Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Markus Magerl

Showing results (131-140 of 152) with videos related to

Pageof 16
Sort By:
Arerugi = [Allergy]|April 12, 2026
Bruce L Zuraw, Konrad Bork, Laurence Bouillet, et al.
Clinical Reviews in Allergy & Immunology|March 7, 2025
Hereditary Angioedema with Normal C1 Inhibitor: an Updated International Consensus Paper on Diagnosis, Pathophysiology, and TreatmentBruce L Zuraw, Konrad Bork, Laurence Bouillet, et al.
The Journal of Allergy and Clinical Immunology. Global|April 25, 2025
Global frequency, diagnosis, and treatment of hereditary angioedema with normal C1 inhibitorMarkus Magerl, Marc A Riedl, Luisa Karla Arruda, et al.
JAMA|November 28, 2018
Effect of Lanadelumab Compared With Placebo on Prevention of Hereditary Angioedema Attacks: A Randomized Clinical TrialAleena Banerji, Marc A Riedl, Jonathan A Bernstein, et al.
The Journal of Allergy and Clinical Immunology. in Practice|February 18, 2019
Long-Term Outcomes with Subcutaneous C1-Inhibitor Replacement Therapy for Prevention of Hereditary Angioedema AttacksTimothy Craig, Bruce Zuraw, Hilary Longhurst, et al.
The World Allergy Organization Journal|November 18, 2020
The usage, quality and relevance of information and communications technologies in patients with chronic urticaria: A UCARE studyMarcus Maurer, Karsten Weller, Markus Magerl, et al.
Clinical and Translational Allergy|December 28, 2021
Chronic urticaria patients are interested in apps to monitor their disease activity and control: A UCARE CURICT analysisIvan Cherrez-Ojeda, Emanuel Vanegas, Annia Cherrez, et al.
The Journal of Allergy and Clinical Immunology. in Practice|August 31, 2025
Long-term Safety and Effectiveness of Sebetralstat: Interim Analysis of KONFIDENT-S Open-label ExtensionHenriette Farkas, John Anderson, Laurence Bouillet, et al.
The World Allergy Organization Journal|June 18, 2021
How are patients with chronic urticaria interested in using information and communication technologies to guide their healthcare? A UCARE studyIvan Cherrez-Ojeda, Emanuel Vanegas, Annia Cherrez, et al.
The Lancet. Haematology|March 22, 2026
Oral deucrictibant for on-demand treatment of hereditary angioedema attacks (RAPIDe-1): a randomised, double-blind, placebo-controlled, phase 2 trialMarcus Maurer, Marcin Stobiecki, Anna Valerieva, et al.
Pageof 16

Showing results (131-140 of 152) with videos related to

Sort By:
Pageof 16
Arerugi = [Allergy]|April 12, 2026
Bruce L Zuraw, Konrad Bork, Laurence Bouillet, et al.
Clinical Reviews in Allergy & Immunology|March 7, 2025
Hereditary Angioedema with Normal C1 Inhibitor: an Updated International Consensus Paper on Diagnosis, Pathophysiology, and TreatmentBruce L Zuraw, Konrad Bork, Laurence Bouillet, et al.
The Journal of Allergy and Clinical Immunology. Global|April 25, 2025
Global frequency, diagnosis, and treatment of hereditary angioedema with normal C1 inhibitorMarkus Magerl, Marc A Riedl, Luisa Karla Arruda, et al.
JAMA|November 28, 2018
Effect of Lanadelumab Compared With Placebo on Prevention of Hereditary Angioedema Attacks: A Randomized Clinical TrialAleena Banerji, Marc A Riedl, Jonathan A Bernstein, et al.
The Journal of Allergy and Clinical Immunology. in Practice|February 18, 2019
Long-Term Outcomes with Subcutaneous C1-Inhibitor Replacement Therapy for Prevention of Hereditary Angioedema AttacksTimothy Craig, Bruce Zuraw, Hilary Longhurst, et al.
The World Allergy Organization Journal|November 18, 2020
The usage, quality and relevance of information and communications technologies in patients with chronic urticaria: A UCARE studyMarcus Maurer, Karsten Weller, Markus Magerl, et al.
Clinical and Translational Allergy|December 28, 2021
Chronic urticaria patients are interested in apps to monitor their disease activity and control: A UCARE CURICT analysisIvan Cherrez-Ojeda, Emanuel Vanegas, Annia Cherrez, et al.
The Journal of Allergy and Clinical Immunology. in Practice|August 31, 2025
Long-term Safety and Effectiveness of Sebetralstat: Interim Analysis of KONFIDENT-S Open-label ExtensionHenriette Farkas, John Anderson, Laurence Bouillet, et al.
The World Allergy Organization Journal|June 18, 2021
How are patients with chronic urticaria interested in using information and communication technologies to guide their healthcare? A UCARE studyIvan Cherrez-Ojeda, Emanuel Vanegas, Annia Cherrez, et al.
The Lancet. Haematology|March 22, 2026
Oral deucrictibant for on-demand treatment of hereditary angioedema attacks (RAPIDe-1): a randomised, double-blind, placebo-controlled, phase 2 trialMarcus Maurer, Marcin Stobiecki, Anna Valerieva, et al.
Pageof 16